Long acting ß2-agonists and glucocorticoids together control asthma in ~95% of affected individuals, although symptoms return after treatment is stopped. Treatment of chronic obstructive pulmonary disease (COPD) scarcely influences the natural course of the disease. Neither long-acting ß2-agonists (LABAs) nor glucocorticoids alone significantly influence the course of COPD. Recent evidence suggests that a combination of the two therapies is more promising. It can decrease the exacerbation rates in severe COPD and may also decrease mortality.
Interactions between long-acting ß2-agonists and glucocorticoids / Caramori, Gaetano; Ito, K.; Papi, A.; Adcock, I. M.. - In: DRUG DISCOVERY TODAY: THERAPEUTIC STRATEGIES. - ISSN 1740-6773. - 3:3(2006), pp. 261-268.
Interactions between long-acting ß2-agonists and glucocorticoids
CARAMORI, Gaetano;
2006-01-01
Abstract
Long acting ß2-agonists and glucocorticoids together control asthma in ~95% of affected individuals, although symptoms return after treatment is stopped. Treatment of chronic obstructive pulmonary disease (COPD) scarcely influences the natural course of the disease. Neither long-acting ß2-agonists (LABAs) nor glucocorticoids alone significantly influence the course of COPD. Recent evidence suggests that a combination of the two therapies is more promising. It can decrease the exacerbation rates in severe COPD and may also decrease mortality.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
